Luxturna and other Spark pipeline candidates use an adeno-associated virus vector (AVV) platform to deliver its gene therapy, a distinct technology which Novartis hasn’t built up expertise in.

Some analysts think Spark could charge as much as $1 million ... Luxturna is a single injection that works by delivering 150 billion viral vector particles containing a correct copy of the RP65 ...